Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gas insufflation. A case report

Tumori

Volumn 98, Issue 3, 2012, Pages

  Ripamonti, Carla Ida ^a   Maniezzo, Massimo ^a   Pessi, Maria Adelaide ^a   Boldini, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Medical ozone gas insufflation; Osteonecrosis of the jaw (ONJ); Zoledronic acid

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; MELPHALAN; OZONE; PIPERACILLIN; STEROID; TAZOBACTAM; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEMIMANDIBULECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; JAW OSTEONECROSIS; MALE; MANDIBLE RESECTION; MANDIBULAR NERVE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOSCLEROSIS; OZONE GAS INSUFFLATION; OZONE THERAPY; PAIN; PANORAMIC RADIOGRAPHY; PATIENT SAFETY; PERIODONTICS;

AGED; ANTI-BACTERIAL AGENTS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; INSUFFLATION; MALE; MANDIBLE; MULTIPLE MYELOMA; OZONE;

EID: 84867053382     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1125.12414     Document Type: Article

References (10)

1. McKeage K, Plosker GL: Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics, 226: 251-268, 2008. (Pubitemid 351271381)
2. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR: Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ, 327: 1-7, 2003.
3. Morgan G, Lipton A: Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol, 37 (Suppl 2): S30-40, 2010.
4. Woo SB, Hellstein JW, Kalmar JR: Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med, 144: 753-761, 2006. (Pubitemid 46780635)
5. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol, 20: 117-120, 2009.
6. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol, 20: 137-145, 2009.
7. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA: Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol, 62: 148-152, 2007. (Pubitemid 46575276)
8. Minguez F, Gómez-Lus ML, Andre J, Cabronero MJ, Prieto J: Antimicrobial activity of ozonized water in determined experimental conditions. Rev Sanid Hig Publica (Madr), 64: 415-423, 1990.
9. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M: Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Preliminary results of a phase I-II study. Oral Oncol, 47: 185-190, 2011.
10. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foà R: Role of ozone therapy in the treatment of osteonecrosis of the jaw in multiple myeloma patients. Haematologica, 92: 1289-1290, 2007. (Pubitemid 350144201)